New test to guide treatment for APDS immune disorder
Treatments studied
Part of Immune system & allergy clinical trials.
This study uses a new blood test to find and monitor people with APDS, a rare immune disease, who may be helped by the drug leniolisib. It aims to improve how doctors screen and track treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older
- You have a confirmed diagnosis of APDS type 1 or type 2 (or have a new genetic change linked to APDS)
- You have not had a bone marrow transplant
- You are willing to provide blood samples for testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called RAY121 (an antibody) for people with certain autoimmune diseases. It aims to see if RAY121 is safe and how the body handles it. If you have one of these conditions and meet the basic health requirements, you might be able to join.
This trial tests a new medicine, RLY-2608, that targets the specific genetic change (PIK3CA mutation) causing overgrowth conditions. It aims to see if the drug can slow or stop the growth of affected tissues.
This study looks at blood or tissue samples from people with certain genetic disorders that affect a key cell communication pathway (JAK-STAT). The goal is to learn more about these disorders and test potential treatments in the lab.
This study looks for genetic causes of immune problems, such as unusually frequent infections, abnormal allergies, or autoimmune or inflammation conditions. It may help by improving how doctors understand these disorders and by matching families with possible genetic diagnoses.
This study looks at immune cells in blood to better understand rare brain conditions caused by genetic changes. It may help researchers understand why symptoms happen and how the immune system is involved.
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
Hear when a new Activated PI3K Delta Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.